(Q37212106)

19 August 2017

The association between weight change and symptom reduction in the CATIE schizophrenia trial (English)

1 reference

19 August 2017

0 references

11

Robert Rosenheck

1 reference

19 August 2017

6

Donald Goff

1 reference

19 August 2017

2

Henry Nasrallah

1 reference

19 August 2017

10

Jeffrey Lieberman

1 reference

19 August 2017

Eric Hermes

1

1 reference

19 August 2017

Vicki Davis

3

1 reference

19 August 2017

Jonathan Meyer

4

1 reference

19 August 2017

Joseph McEvoy

5

1 reference

19 August 2017

Sonia Davis

7

1 reference

19 August 2017

T Scott Stroup

8

1 reference

19 August 2017

Marvin Swartz

9

1 reference

19 August 2017

language of work or name

English

0 references

publication date

21 February 2011

1 reference

19 August 2017

Schizophrenia Research

1 reference

19 August 2017

128

1 reference

19 August 2017

1-3

1 reference

19 August 2017

166-170

1 reference

Extrapyramidal side-effects of antipsychotics in a randomised trial

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Association of initial antipsychotic response to clozapine and long-term weight gain

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

A meta-analysis of the efficacy of second-generation antipsychotics

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Antipsychotic-associated weight gain and clinical outcome parameters

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Bodyweight gain with atypical antipsychotics. A comparative review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Antipsychotic-induced weight gain: a comprehensive research synthesis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

The positive and negative syndrome scale (PANSS) for schizophrenia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Differential effect of clozapine on weight: a controlled study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

What does the PANSS mean?

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Clozapine-induced weight gain predicts improvement in psychopathology

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Antipsychotic-induced weight gain and therapeutic response: a differential association.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Detecting improvement in quality of life and symptomatology in schizophrenia

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Olanzapine: weight gain and therapeutic efficacy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789238

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21334853

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Why do schizophrenic patients refuse to take their drugs?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21334853

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.SCHRES.2011.01.022

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

21334853

1 reference